EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS

被引：0
|
作者：
Shen, Z. [1 ]
Huang, X. [2 ]
Meng, F. [3 ]
Wang, J. [4 ,5 ,8 ]
Liu, T. [6 ]
Hu, J. [7 ]
Wang, J. [4 ,5 ,8 ]
Zhao, Y. [9 ]
Woodman, R. [8 ]
Zou, P. [10 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China
[2] Beijing Univ, Beijing 100871, Peoples R China
[3] Nanfang Med Univ, Guangzhou, Guangdong, Peoples R China
[4] Chinese Acad Med Sci, Tianjin, Peoples R China
[5] Peking Union Med Coll, Tianjin, Peoples R China
[6] Sichuan Univ, Chengdu 610064, Peoples R China
[7] Fujian Med Univ, Affiliated Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut Co Ltd, Beijing, Peoples R China
[10] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430074, Peoples R China
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0865
引用
收藏
页码：348 / 349
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure
    Onaka, Takashi
    Takahashi, Naoto
    Miura, Masatomo
    Yonezawa, Akihito
    Imada, Kazunori
    Sawada, Kenichi
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (04) : 451 - 451
  • [32] Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
    Francis J. Giles
    Ophelia Q. P. Yin
    William M. Sallas
    Philipp D. le Coutre
    Richard C. Woodman
    Oliver G. Ottmann
    Michele Baccarani
    Hagop M. Kantarjian
    European Journal of Clinical Pharmacology, 2013, 69 : 813 - 823
  • [33] Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
    Giles, Francis J.
    Yin, Ophelia Q. P.
    Sallas, William M.
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 813 - 823
  • [34] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [36] NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES
    Yavuz, Akif Selim
    Elcioglu, Omer Celal
    Akpinar, Timur
    Cosan, Fulya
    Ucur, Ali
    Bayrak, Ayseguel
    Cefle, Kivanc
    Ozturk, Suekrue
    Palanduz, Suekrue
    Yenerel, Mustafa Nuri
    Aktan, Melih
    Nalcaci, Meliha
    NOBEL MEDICUS, 2010, 6 (02): : 57 - 62
  • [37] ANALYSIS OF BCR-ABL MUTATIONS IN MEXICAN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH plus CML) TREATED WITH NILOTINIB
    Ayala, J. L.
    Hurtado, R.
    Delgado, N.
    Vargas, P.
    Meillon, L.
    Tapia, N.
    Alvarado, M.
    De Diego, J.
    Azaola, P.
    Gonzalez, M.
    Lugo, Y.
    Hernandez, R.
    Kassack, J. J.
    Cleto, S.
    Nambo, M.
    Reyes, G.
    Cantu, O.
    Aguayo, A.
    Mucius, I.
    Herrera, A.
    Nacho, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 220 - 220
  • [38] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [39] NILOTINIB IN IMATINIB-RESISTANT OR -INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE (CML-AP): UPDATE OF A PHASE 2 STUDY
    le Coutre, P.
    Giles, F. J.
    Hochhaus, A.
    Apperley, J.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 47 - 47
  • [40] Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients (pts)treated with nilotinib: Lack of correlation between glucose levels and nilotinib efficacy.
    le Coutre, Philipp
    Giles, Francis J.
    Hochhaus, Andreas
    Martinelli, Giovanni
    Wang, Jim
    Passos, Vanessa
    Kayath, Marcia
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 219B - 219B
12345